VERX 240920 35.00P (VERX240920P35000) Stock Options, News & Quotes

0.55
0.000.00%

15min DelayClose Sep 12 16:00 ET

0.55High0.55Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Sanjeev Kaushik

May 30 05:44

Biotech Investment Ideas

Explore these stocks poised to benefit from innovations in biotech:
AstraZeneca: AstraZeneca is a leading biopharmaceutical company focused on developing innovative medicines, especially for rare diseases and metabolic disorders.
Novartis: Novartis is a global healthcare company pioneering innovative medical solutions, especially tackling rare genetic diseases through cutting-edge research and development.
Amgen: With a strong focus on rare diseases and oncology, Amgen ai...

NASSER09

Apr 23 12:00

$Vertex (VERX.US)$ they buy with huge mony any news!!?

Moomoo AI

Mar 27 12:22

Vertex's leadership is excited about the acquisition of TriLogix, expecting it to enhance their commitment to providing top-notch construction project control services.

Press Release: The Vertex Companies, LLC Acquires TriLogix Consulting, LLC

Moomoo AI

Feb 12 06:07

Analysts predict Vertex to breakeven in less than a year, with an estimated yearly growth rate of 123%. If this rate is too optimistic, profitability may be delayed. The company's low debt reduces investment risk in the loss-making company.

Vertex, Inc. (NASDAQ:VERX) About To Shift From Loss To Profit

Moomoo AI

Jan 30 14:43

Analysts believe that if approved, VX-548 could generate over $5B in annual sales for Vertex. Despite the trials not showing superiority over opioids, the safety and addiction advantage of the drug is seen as a significant benefit.

Vertex Pharma Hits 52-week High on Addiction-free Pain Med